anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The newly introduced ultrasound guided interfacial rhomboid intercostal and sub-serratus (RISS) block technique demonstrated promising efficacy in managing perioperative pain among patients undergoing abdominal and thoracic procedures. Thus, this study investigated the efficiency of bilateral ultrasound-guided RISS (US-RISS) as a perioperative pain control technique in male subjects receiving gynecomastia surgery.
METHODS: This prospective randomized study involved sixty patients who underwent gynecomastia surgery. Individuals were randomly divided into two groups: the RISS group (N.=30) and the control group (N.=30). After anesthesia induction, the patients received bilateral US-RISS using 40 mL of 0.25% levobupivacaine, or conventional intravenous analgesia with no intervention, respectively. The primary outcome was the overall morphine consumption in 24 hours, and the secondary endpoints involved the time elapsed till rescue analgesia was requested, the quality of recovery after 24 hours and side effects' incidence.
RESULTS: Morphine consumption was noticeably decreased in the RISS group compared to the control group, with 14.07±4.91 mg and 35.83±1.70 mg mean values, respectively (P<0.001). Furthermore, in the RISS group, the initial rescue analgesia request occurred significantly later than in the control group, with mean values of 15.58±1.41 hours and 0.96±0.63 hours, respectively (P<0.001). Additionally, within the RISS group, there was a high quality of recovery observed, with a low incidence of opioid-related adverse events in comparison to the control group.
CONCLUSIONS: Bilateral US-RISS block is a beneficial intervention in gynecomastia surgery for pain management and improves the quality of recovery.
Refractory vasodilatory shock, or vasoplegia, is a pathophysiologic state observed in the intensive care unit and operating room in patients with a variety of primary diagnoses. Definitions of vasoplegia vary by source but are qualitatively defined clinically as a normal or high cardiac index and low systemic vascular resistance causing hypotension despite high-dose vasopressors in the setting of euvolemia. This definition can be difficult to apply to patients undergoing mechanical circulatory support (MCS). A large body of mostly retrospective literature exists on vasoplegia in the non-MCS population, but the increased use of temporary MCS justifies an examination of vasoplegia in this population. MCS, particularly extracorporeal membrane oxygenation, adds complexity to the diagnosis and management of vasoplegia due to challenges in determining cardiac output (or total blood flow), lack of clarity on appropriate dosing of noncatecholamine interventions, increased thrombosis risk, the difficulty in determining the endpoints of adequate volume resuscitation, and the unclear effects of rescue agents (methylene blue, hydroxocobalamin, and angiotensin II) on MCS device monitoring and function. Care teams must combine data from invasive and noninvasive sources to diagnose vasoplegia in this population. In this narrative review, the available literature is surveyed to provide guidance on the diagnosis and management of vasoplegia in the temporary MCS population, with a focus on noncatecholamine treatments and special considerations for patients supported by extracorporeal membrane oxygenation, transvalvular heart pumps, and other ventricular assist devices.
BACKGROUND: Radiologic ulcers are increasingly recognized as an imaging finding of bowel wall active inflammation in Crohn disease (CD).
OBJECTIVE: To determine the frequency of ulcers at MR enterography (MRE) in children with newly diagnosed ileal CD, assess agreement between radiologists, and evaluate if their presence correlates with other imaging and clinical features of intestinal active inflammation.
MATERIALS AND METHODS: This retrospective study included 108 consecutive pediatric patients (ages 6-18 years) with newly diagnosed ileal CD that underwent clinical MRE prior to treatment initiation between January 2021 and December 2022. MRE examinations were independently reviewed by three pediatric radiologists who indicated the presence vs. absence of ulcers, ulcer severity (categorical depth), and ulcer extent (categorical number of ulcers). Maximum bowel wall thickness and length of disease were measured and averaged across readers. Patient demographics and clinical inflammatory markers were documented from electronic health records. Inter-radiologist agreement was assessed using Fleiss' kappa (k) statistics. Student's t-test was used to compare continuous variables.
RESULTS: Mean patient age was 13.9 years (67 [62%] boys). Radiologic ulcers were recorded in 64/108 (59.3%) cases by reader 1, 70/108 (64.8%) cases by reader 2, and 49/108 (45.4%) cases by reader 3 (k = 0.36). Based on majority consensus, radiologic ulcers were present in 60/108 (55.6%) participants. Inter-radiologist agreement for ulcer severity was k = 0.23, while ulcer extent was k = 0.66. There were significant differences in C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, albumin, maximum bowel wall thickness, and length of disease between patients without and with radiologic ulcers (P < 0.05). The sensitivity and specificity of MRE for detecting endoscopic ulcers were 66.7% (95% CI, 52.1-79.2%) and 69.2% (95% CI, 48.2-85.7%), respectively.
CONCLUSION: Radiologic ulcers are visible in children with newly diagnosed ileal CD, although inter-radiologist agreement is only fair. The presence of ulcers is associated with clinical laboratory inflammatory markers as well as other MRE findings of disease activity and is an additional imaging finding that can be used to evaluate intestinal inflammation.
10.1 Signs and Symptoms

Acute overdose with Oxycodone Hydrochloride Oral Solution, USP can be manifested by respiratory depression (a decrease in respiratory rate and/or end tidal volume. Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, pulmonary edema, cardiac arrest, and death.

Oxycodone Hydrochloride Oral Solution, USP may cause miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [see Clinical Pharmacology (12)] . 

10.2 Treatment

Give primary attention to the reestablishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures including oxygen and vasopressors should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

The pure opioid antagonists, naloxone or nalmefene, are specific antidotes to respiratory depression resulting from opioid overdose. Since the duration of reversal is expected to be less than the duration of action of oxycodone hydrochloride, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to opioid antagonists is suboptimal or only brief in nature, administer additional antagonist as directed by the manufacturer of the product.

Do not administer opioid antagonists in the absence of clinically significant respiratory or circulatory depression secondary to oxycodone overdose. Administer such agents cautiously to persons who are known, or suspected to be physically dependent on oxycodone. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome.

In an individual physically dependent on opioids, administration of the usual dose of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. Reserve use of an opioid antagonist for cases where such treatment is clearly needed. If it is necessary to treat serious respiratory depression in the physically dependent patient, initiate administration of the antagonist with care and titrate with smaller than usual doses.
FIELD: medicine. SUBSTANCE: method involves milling spleen, extraction with an aqueous extractant, separation of an aqueous extract, dialysis and lyophilization. Extraction is combined by the simultaneous low-frequency ultrasonic treatment. An aqueous extract is separated by centrifugation. Weight ratio of spleen and water can be 1/6-1/3. Dialysis of an aqueous extract is carried out at molecular mass value below 50000 Da. Ultrasonic frequency is at the range 18-70 kHz at intensity 0.1-2.3 W/cm. EFFECT: increased yield of the end product, decreased process time. 6 cl, 1 tbl
A card type portable terminal for measuring a bio signal is provided to test a pulse wave and an electrocardiogram without going to hospital by using two electrodes and at least one photo sensor. A card type portable terminal includes an electrocardiogram electrode part(110), a sensor unit(120), a controller(130) and a wireless communications unit(140). An electrocardiogram electrode part includes a first electrode(113) and a second electrode(115). The first electrode is arranged in the front side of the body. The second electrode is arranged in the first side surface of the body. The electrocardiogram electrode part measures the electrocardiogram signal through the first electrode and the second electrode. The sensor unit is arranged in the second side of the body in order to measure the pulse wave signal. The controller is arranged inside the portable terminal. The controller analyzes the electrocardiogram signal and the pulse wave signal received from the electrocardiogram electrode part and the sensor unit. The wireless communication unit transmits the analyzed result by the control of the controller.
The present invention relates to a use of screening a therapeutic agent for cancer using interaction of a TMBIM6 promoter with Sp1 or PKC. TMBIM6 is upregulated in several types of cancer and is involved in metastasis. Specific downregulation of TMBIM6 has been known to cause cancer cells to die, but the regulation of TMBIM6 gene transcription in normal and cancer cells has hardly been studied. Meanwhile, the inventors revealed a key promoter region (-133/+30 bp) essential for the promoter activity of the TMBIM6 gene, and revealed that Sp1 is a transcription factor essential for the basic promoter activity of TMBIM6. In addition, the inventors confirmed that protein kinase-C (PKC) activation promotes the promoter activity and endogenous TMBIM6 mRNA 2- to 2.5-fold. Additionally, it was confirmed that the expression levels of PKCι, Sp1 and TMBIM6 were correlated with each other in samples derived from patients with breast cancer, prostate cancer and liver cancer. Based on the above-mentioned results, the present invention can be usefully utilized to establish an innovative strategy for the treatment of certain forms of cancer and to screen therapeutic agents for cancer.
The subject invention concern materials and methods for cryopreservation of HCG-cell constructs. In one embodiment, porous HCG scaffolds are provided in a perfusion bioreactor having perfusion chambers that can contain the HCG scaffolds, cells are then seeded in the HCG scaffolds in the perfusion bioreactor, cell culture media is perfused through and the bioreactor operated so as to allow for cell seeding and growth in the HCG scaffold. After a suitable period of time, the cell culture media is removed and the HCG containing cells (HCG-cell constructs) can be washed with a suitable buffer, such as phosphate-buffered saline (PBS). The HCG-cell constructs are then perfused in the bioreactor with a suitable cryopreservation fluid. The cryopreservant can comprise one or more of the following: DMSO, trehalose, glycerol, ethylene glycol, and serum for cell culture (e.g., fetal bovine serum (FBS)). In one embodiment, the HCG-cell constructs are perfused for a suitable period of time with cryopreservant fluid using transverse flow of the fluid in the bioreactor at a suitable flow rate. The HCG-cell constructs (or the perfusion chambers containing them) are then removed from the bioreactor and placed in a cryopreservant media and maintained at increasingly colder temperatures until temperatures reach about −80° C. The frozen HCG-cell constructs (or the chambers containing them) can then be stored at a suitable cryogenic temperature (e.g., in liquid nitrogen) until needed. When needed, frozen HCG-cell constructs can be removed from cold storage and thawed using suitable means (e.g., 37° C. water bath). Cells contemplated for use in the present invention include stem cells, such mesenchymal stem cells. Cells can be animal cells, such as mammalian cells. In one embodiment, the cells are human cells.
PURPOSE: A crude drug composition which reduces blood glucose and a method for manufacturing the same are provided to prevent and treat diabetes(type 1 and type 2) and to reduce low density lipoprotein(LDL). CONSTITUTION: A crude drug composition contains 100 parts by weight of black garlic, 62.5-850 parts by weight of balsam pear, 250-2500 parts by weight of edible snail, 0.375-4.5 parts by weight of cocoon protein hydrolysate, 7.5 parts by weight of a ginkgo leaf extract, and 0.0075-0.4 parts by weight of L-lysine. A method for manufacturing the composition comprises: a step of adding black garlic, balsam pear, and yam to an ethanol solution and maturing the mixture at 0-5 deg. C.(S10); a step of adding the ginkgo leaf extract and edible snail to the supernatant of the mixture and maturing at 0-5 deg.C.(S20); a step of adding L-lysine and maturing at 0-5 deg.C.(S30); a step of adding cocoon protein hydrolysate and maturing at 0-5 deg.C.(S40); and a step of volatilizing and removing the ethanol ingredients(S50). [Reference numerals] (S10) First maturing step of adding black garlic, balsam pear, and yam to an ethanol solution and maturing; (S20) Second maturing step of adding ginkgo leaf extract and edible snail to the supernatant of the mixture, manufactured from the first maturing step, and maturing; (S30) Third maturing step of adding L-lysine to the supernatant of the mixture, manufactured from the second maturing step, and maturing; (S40) Fourth maturing step of adding cocoon protein hydrolysate to the supernatant of the mixture, manufactured from the third maturing step, and maturing; (S50) Step of obtaining a crude drug composition by volatilizing and removing ethanol ingredients manufactured from the fourth maturing step
BACKGROUND: In Japan, sentinel surveillance is used to monitor the trend of infectious gastroenteritis. Another method of pathogen surveillance, wastewater-based epidemiology, has been used recently because it can help to monitor infectious disease without relying on patient data. Here, we aimed to determine the viral trends reflected in the number of reported patients and number of gastroenteritis virus-positive samples. We focused on gastroenteritis viruses present in wastewater and investigated the usefulness of wastewater surveillance for the surveillance of infectious gastroenteritis.
METHODS: Real-time polymerase chain reaction was used for viral gene detection in wastewater. The number of reported patients per pediatric sentinel site and number of viral genome copies were compared for correlation potential. The number of gastroenteritis virus-positive samples reported by National Epidemiological Surveillance of Infectious Disease (NESID) and the status of gastroenteritis viruses detected in wastewater were also evaluated.
RESULTS: Genes of norovirus genotype I, norovirus genotype II, sapovirus, astrovirus, rotavirus group A, and rotavirus group C were detected in wastewater samples. Viruses were detected in wastewater during periods when no gastroenteritis virus-positive samples were reported to NESID.
CONCLUSION: Norovirus genotype II and other gastroenteritis viruses were detected in wastewater even during periods when no gastroenteritis virus-positive samples were found. Therefore, surveillance using wastewater can complement sentinel surveillance and is an effective tool for the surveillance of infectious gastroenteritis.
The invention relates to the technical field of medicines. A medicament for treating and preventing ophthalmic diseases, which is characterized in that: the medicine contains osthole and/or osthole derivatives. The osthole and the derivatives thereof are used for treating partial ophthalmic diseases, and a new treatment idea is provided for diseases related to ophthalmic diseases such as fibrosis and other extracellular matrix protein abnormalities. The medicine can be used for treating and preventing ophthalmic diseases caused by extracellular matrix protein abnormality. The ophthalmic disease may be glaucoma. The ophthalmic disease may be conjunctival scarring, pseudoptosis, ocular skin scarring, age-related macular degeneration, diabetic retinopathy or secondary cataract. The ophthalmic diseases can be surgical treatment failure caused by filtering channel scarring after trabeculectomy and filtering channel scarring after trabeculectomy.
Arm designed as an active comparator with standard (protective) ventilatory settings (n=50). Tidal volumes (Vt) will be set for 8ml/kg.
After baseline collection of serum and fecal microbiota, each subject will be administered the probiotic formulation VSL#3 450 Billion CFU Twice daily for 8 weeks. Serum and fecal microbiota will again be collected at the end of the intervention and compared with baseline with each subject serving as his or her own control.
Gastrin is a gastrointestinal peptide hormone that plays an important role in the progression of colorectal cancer (CRC). However, the molecular mechanism remains unclear. In this study, we identified gastrin-related circRNAs via high-throughput sequencing and selected circRNA_0017065 as the research focus. We further studied its specific role and molecular mechanism in the progression of CRC. Knockdown and overexpression of circRNA_0017065 were performed, and the biological function of circRNA_0017065 in CRC progression was studied via in vitro and in vivo functional experiments. The potential downstream target genes were subsequently identified via screening of databases and gene chip data. The expression of circRNA_0017065 in tumour tissues was significantly upregulated compared with that in adjacent normal tissues. In vitro and in vivo functional experiments revealed that the proliferation and migration of CRC cells were significantly suppressed after circRNA_0017065 knockdown, while apoptosis was promoted. After overexpression of circRNA_0017065, the proliferation and migration of CRC cells were significantly promoted, while apoptosis was inhibited. Mechanistic studies revealed that circRNA_0017065 can act as a sponge for miR-3174 and promote CRC progression via the miR-3174/RBFOX2 axis. In general, gastrin-related circRNA_0017065 plays a key role in the occurrence and development of CRC and is expected to be a potential molecular target for the treatment of CRC metastasis.
FIELD: chemistry of heterocyclic compounds, organic chemistry and technology, biochemistry. SUBSTANCE: invention relates to derivatives of oxazolidone of the formula (I) R 1  where A and B each means nitrogen, sulfur or oxygen atom at condition that at least one of their must be nitrogen atom. R 2  and   have different values indicated in description, and pharmaceutical composition and a method of treatment based on thereof. Synthesized compounds are inhibitors of monoamine oxidase. EFFECT: improved method of synthesis, enhanced effectiveness of compounds synthesized. 17 cl, 9 tbl, 59 ex
PROBLEM TO BE SOLVED: To obtain a composition especially usable in a cosmetic and/or a demographic field, locally applicable to a face including the periphery of an eye, a body and a scalp. SOLUTION: This composition contains ascorbic acid and a polyol. The composition contains 0.05-10wt.% of ascorbic acid and 30-99.99wt.% of a polyol so as to make the water activity value of the composition <=0.85, preferably <=0.7 in order to avoid deterioration of ascorbic acid. The composition further comprises at least one selected from among a polymer and an oil. the polyol is selected from among glycerol and a glycol. The polymer is selected from among an acrylic polymer and a methacrylic polymer and further contains bound water. The composition has 70-99.99wt.% content of the polymer, the polyol and the bound water and 5-60wt.% content of the oil and is prepared in the form a gel or an emulsion.
Eating disorders are serious mental illnesses associated with significant morbidity and high relapse rates. Patients are at especially high risk of relapse after leaving structured treatment (e.g., hospitalization). Adjunct interventions targeting patients' motivation and participation in treatment at these times may help patients recover from eating disorders. Project HEAL is a non-profit organization whose mission is to reduce suffering caused by eating disorders, and they have recently developed two adjunct, mentorship-based interventions for patients in recovery. In the peer mentorship condition, individuals meet weekly with a peer mentor who has previously recovered from an eating disorder in order to discuss symptoms and coping strategies. In the social support mentorship condition, individuals meet weekly with a social support mentor who has not personally struggled with an eating disorder in order to engage in activities unrelated to the eating disorder. The aim of the current study is to evaluate the feasibility and efficacy of this intervention. The design of the study is a three-arm randomized controlled trial comparing peer mentorship, social-support mentorship, and wait-list control conditions. Participants in the study will be randomized to one of the three conditions for six months. Wait-list participants will subsequently receive either type of mentorship. Participants will complete assessments of their eating disorder symptoms at baseline, monthly throughout the course of the study, and one year after beginning the study. Outcomes will be compared between groups.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of ranibizumab or of other ranibizumab products.

The pre-treatment incidence of immunoreactivity to ranibizumab was 0%-5% across treatment groups. After monthly dosing with ranibizumab for 6 to 24 months, antibodies to ranibizumab were detected in approximately 1%-9% of patients.

The clinical significance of immunoreactivity to ranibizumab products is unclear at this time. Among neovascular AMD patients with the highest levels of immunoreactivity, some were noted to have iritis or vitritis. Intraocular inflammation was not observed in patients with DME and DR at baseline, or RVO patients with the highest levels of immunoreactivity.